Presenter: W. Todd Penberthy, PhD
The B3 vitamins are by definition the essential dietary precursors to nicotinamide adenine dinucleotide (NAD). NAD is central to bioenergetic and metabolic homeostasis. NAD deficiencies are at the heart of chronic disease susceptibility in the human body machine, while B3 vitamers (niacin, nicotinamide, nicotinamide riboside, or nicotinamide mononucleotide) can contribute to complementary rescuing of NAD deficiencies to eliminate disease presentations. Niacin however, has distinct advantages compared to the other vitamers including an exceptional ability to correct lipodystrophy, elevating HDL levels more than any known pharmaceutical, and niacin provides a vasodilation (“flush”) working on the same pathway as Tecfidera (multiple sclerosis). The niacin-unique vasodilatory component likely contributes to exceptional delivery of said NAD precursors and anything else co-supplemented to otherwise inaccessible tissues. High-dose niacin or related therapies have been used with demonstrable success in the clinic to treat or prevent lipodystrophy/CVD, schizophrenia, neurodegenerative diseases with bioenergetic components (Alzheimer’s, etc..), alcoholism, tapering off psychiatric medications/detoxification/P450, sarcopenia, and autoimmune diseases. A review of clinical indications demonstrably most responsive to high-dose niacin therapy or related vitamers with consideration of Abram Hoffer’s unprecedented clinical legacy is presented with B3 administration details from reports.
